⌕
Savara · SVRA · Nasdaq
Tenet 32 · Weak
Compare
$4.64−1.69%At closeTenet 32 · Weak
$4.64−0.08 (−1.69%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

Savara (SVRA) Stock

Savara (SVRA) closed at $4.64 on Nov 13, 2026; its Tenet Score is 32 of 100 against 409 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

39 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$4.64
Nov 13, 2026
Market cap
$1.0B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
4.03 – 7.00
low → high
Tenet Score
32/100
Weak · 409 Healthcare peers

Industry: Drugs · see every company filed here →

Savara Inc scores 32/100. Weak. Strongest on financial health, quality is the soft spot versus 409 Healthcare peers. Insufficient inputs: Tenet 32 is built from 3 of 4 pillars, from 35% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=409
32/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
18
Quality
9
Health
68
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueFQualityFHealthCGrowth—MomentumC
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
9.5×
price to book value
P/S
—
no P/S on file
ROE
−151%
return on equity
Operating margin
—
no operating margin on file
Net margin
—
Not meaningful: revenue is too small to measure a margin against.
Current ratio
8.55
current assets to liabilities
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=409) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 53 US ETFs · top wrappers by weightSee all ETFs holding SVRA →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Savara in?

Savara is in the Healthcare sector and the Drugs industry.

What is Savara's Tenet Score?

Savara's Tenet Score is 32 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.